HES
MCID: HYP098
MIFTS: 63

Hypereosinophilic Syndrome (HES) malady

Categories: Rare diseases, Immune diseases, Blood diseases, Genetic diseases

Aliases & Classifications for Hypereosinophilic Syndrome

Aliases & Descriptions for Hypereosinophilic Syndrome:

Name: Hypereosinophilic Syndrome 12 50 24 52 42 14 69
Eosinophilia 12 29 52 42 14 69
Hes 50 45
Disseminated Eosinophilic Collagen Disease 69
Hypereosinophilic Syndrome, Idiopathic 50
Idiopathic Hypereosinophilic Syndrome 69
Eosinophilic Leukocytosis 12
Eosinophilic Disorder 69

Classifications:



External Ids:

Disease Ontology 12 DOID:999
ICD10 33 D72.1
ICD9CM 35 288.3
UMLS 69 C0014457

Summaries for Hypereosinophilic Syndrome

NIH Rare Diseases : 50 hypereosinophilic syndrome is a group of rare blood disorders characterized by increased levels of eosinophils (a type of white blood cell that plays a role in the human immune system) persisting for more than six months. the signs and symptoms are due to involvement of several internal organs and there is usually no evidence of parasites, allergy, or other known causes of an elevated eosinophil count. this condition largely occurs in males, typically at middle age. it usually presents with fever, weight loss, fatigue, and rash. an enlarged liver and spleen and liver is often present. the lungs, kidneys, heart, and nervous system can also be affected. last updated: 7/11/2011

MalaCards based summary : Hypereosinophilic Syndrome, also known as eosinophilia, is related to restrictive cardiomyopathy and lymphoblastic leukemia, and has symptoms including pruritus, myalgia and abdominal pain. An important gene associated with Hypereosinophilic Syndrome is PDGFRA (Platelet Derived Growth Factor Receptor Alpha), and among its related pathways/superpathways are ERK Signaling and Innate Immune System. The drugs Nitric Oxide and Montelukast have been mentioned in the context of this disorder. Affiliated tissues include heart, liver and bone, and related phenotypes are Decreased viability and hematopoietic system

Wikipedia : 71 The hypereosinophilic syndrome (HES) is a disease characterized by a persistently elevated eosinophil... more...

Related Diseases for Hypereosinophilic Syndrome

Diseases in the Hypereosinophilic Syndrome family:

Secondary Hypereosinophilic Syndrome Primary Hypereosinophilic Syndrome

Diseases related to Hypereosinophilic Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 257)
id Related Disease Score Top Affiliating Genes
1 restrictive cardiomyopathy 30.2 FIP1L1 IL5 PDGFRA RNASE3
2 lymphoblastic leukemia 29.8 CCL11 IL13 IL5
3 hemophagocytic lymphohistiocytosis 28.6 ABL1 CSF2 IL2RA IL3 KIT PDGFRB
4 eosinophilia-myalgia syndrome 12.2
5 myeloproliferative disorder with eosinophilia 12.1
6 primary hypereosinophilic syndrome 12.1
7 hypereosinophilic syndrome, idiopathic, resistant to imatinib 12.1
8 lymphocytic hypereosinophilic syndrome 12.0
9 secondary hypereosinophilic syndrome 12.0
10 endomyocardial fibrosis 11.2
11 episodic angioedema with eosinophilia 10.9
12 chronic eosinophilic leukemia 10.7
13 ganglioneuroma 10.3 FIP1L1 KIT PDGFRA
14 weaver syndrome 10.3 FIP1L1 PDGFRA RNASE3
15 dfnb1 10.3 KIT PDGFRA PDGFRB
16 olfactory nerve disease 10.3 FIP1L1 KIT PDGFRA
17 myeloid and lymphoid neoplasms associated with fgfr1 abnormalities 10.3 FGFR1 PDGFRA PDGFRB
18 global developmental delay-lung cysts-overgrowth-wilms tumor syndrome 10.3 PRG2 RNASE3
19 leukemia 10.3
20 abdominal obesity-metabolic syndrome 10.3 FGFR1 PDGFRA PDGFRB
21 multifocal osteogenic sarcoma 10.3 KIT PDGFRA PDGFRB
22 invasive mole 10.2 KIT PDGFRA
23 dupuytren contracture 10.2 FGFR1 KIT PDGFRB
24 lens-induced iridocyclitis 10.2 IL2RA IL5 RNASE3
25 autosomal dominant proximal renal tubular acidosis 10.2 FGFR1 FIP1L1 PDGFRA PDGFRB
26 latent syphilis 10.2 CCL11 IL5 RNASE3
27 brown shrimp allergy 10.2 IL2RA IL5 RNASE3
28 cerebral primitive neuroectodermal tumor 10.2 CCL11 IL5 RNASE3
29 orbital margin, hypoplasia of 10.2 FIP1L1 IFNA1 PDGFRA PDGFRB
30 oral leukoedema 10.2 FGFR1 KIT PDGFRA
31 infectious anterior uveitis 10.2 CXCL8 IL5 RNASE3
32 thrombosis 10.2
33 dahlberg borer newcomer syndrome 10.2 IL13 IL5
34 breast intracanalicular fibroadenoma 10.2 CXCL8 FGFR1 IL5
35 astrocytoma 10.2 CCL17 IL5 RNASE3
36 cutaneous fibrous histiocytoma 10.2 CCL11 IL2RA IL5
37 small intestine lymphoma 10.2 CXCL8 IL5 RNASE3
38 dissociated nystagmus 10.2 CCL17 EPX IL5
39 middle lobe syndrome 10.1 CCL17 CXCL8 IL5
40 temporomandibular ankylosis 10.1 FGFR1 FIP1L1 KIT PDGFRA PDGFRB
41 lymphoma 10.1
42 thelaziasis 10.1 CCL11 IL13 IL5
43 arteriosclerosis obliterans 10.1 ABL1 PDGFRB
44 adenosarcoma 10.1 KIT PDGFRA PDGFRB
45 spastic diplegia 10.1 CCL11 IL13 IL5
46 isolated klippel-feil syndrome 10.1 IGHE IL2RA IL5
47 peptidic growth factors deficiency 10.1 CCL11 IL5
48 disordered steroidogenesis due to cytochrome p450 oxidoreductase 10.1 CCL11 IL13 IL5
49 erythrocytosis, somatic 10.1 IFNA1 IL3 KIT PDGFRA PDGFRB
50 actinic keratosis 10.1 IL13 IL5 RNASE3

Comorbidity relations with Hypereosinophilic Syndrome via Phenotypic Disease Network (PDN):


Acute Cystitis Bronchitis
Deficiency Anemia Heart Disease
Hypertension, Essential Ischemic Heart Disease

Graphical network of the top 20 diseases related to Hypereosinophilic Syndrome:



Diseases related to Hypereosinophilic Syndrome

Symptoms & Phenotypes for Hypereosinophilic Syndrome

UMLS symptoms related to Hypereosinophilic Syndrome:


pruritus, myalgia, abdominal pain, angina pectoris, chest pain, constipation, coughing, diarrhea, dyspepsia, edema, heartburn, icterus, nausea and vomiting, snoring, gastrointestinal gas

GenomeRNAi Phenotypes related to Hypereosinophilic Syndrome according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00173-A 9.91 PDGFRA
2 Decreased viability GR00221-A-1 9.91 ABL1 FGFR1 KIT PDGFRA PDGFRB
3 Decreased viability GR00221-A-2 9.91 ABL1 FGFR1
4 Decreased viability GR00221-A-3 9.91 PDGFRB ABL1 PDGFRA
5 Decreased viability GR00221-A-4 9.91 PDGFRB PDGFRA
6 Decreased viability GR00301-A 9.91 KIT
7 Decreased viability GR00342-S-1 9.91 PDGFRB ABL1
8 Decreased viability GR00342-S-2 9.91 ABL1
9 Decreased viability GR00342-S-3 9.91 ABL1
10 Decreased substrate adherent cell growth GR00193-A-1 9.63 KIT
11 Decreased substrate adherent cell growth GR00193-A-2 9.63 ABL1 KIT
12 Decreased substrate adherent cell growth GR00193-A-4 9.63 ABL1 FGFR1 KIT
13 Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) GR00104-A-0 8.92 CSF2 CXCL8 IL2RA PDGFRB

MGI Mouse Phenotypes related to Hypereosinophilic Syndrome:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.97 ABL1 CCL11 CCL17 CSF2 EPX FGFR1
2 digestive/alimentary MP:0005381 9.86 ABL1 FGFR1 IL13 IL2RA IL5 KIT
3 immune system MP:0005387 9.77 PRG2 ABL1 CCL11 CCL17 CSF2 EPX
4 respiratory system MP:0005388 9.28 ABL1 CCL11 CSF2 IL13 IL2RA IL5

Drugs & Therapeutics for Hypereosinophilic Syndrome

Drugs for Hypereosinophilic Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 289)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nitric Oxide Approved Phase 4,Phase 2 10102-43-9 145068
2
Montelukast Approved Phase 4,Phase 3,Phase 1 158966-92-8 5281040
3
Budesonide Approved Phase 4,Phase 3,Phase 2 51333-22-3 63006 5281004
4
Omalizumab Approved, Investigational Phase 4,Phase 2,Phase 1 242138-07-4
5
Histamine Approved, Investigational Phase 4,Phase 3 75614-87-8, 51-45-6 774
6
Prednisolone Approved, Vet_approved Phase 4,Phase 3 50-24-8 5755
7
Lansoprazole Approved, Investigational Phase 4,Phase 2,Phase 1 103577-45-3 3883
8
Ciclesonide Approved, Investigational Phase 4 126544-47-6, 141845-82-1 444033
9
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3 83-43-2 6741
10
Vancomycin Approved Phase 4 1404-90-6 441141 14969
11
Menthol Approved Phase 4 2216-51-5 16666
12
Fluticasone Phase 4,Phase 3,Phase 2 90566-53-3, 80474-14-2 62924 22833648
13 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1
14 Cromolyn Sodium Phase 4
15 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1
16 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
17 Hormones Phase 4,Phase 3,Phase 2,Phase 1
18 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
19 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
20 Anti-Allergic Agents Phase 4,Phase 3,Phase 2,Phase 1
21 Anti-Asthmatic Agents Phase 4,Phase 3,Phase 2,Phase 1
22 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1
23 Antibodies, Monoclonal Phase 4,Phase 3,Phase 2,Phase 1
24 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
25 Leukotriene Antagonists Phase 4,Phase 3,Phase 1
26 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1
27 Antibodies Phase 4,Phase 3,Phase 2,Phase 1
28 Autonomic Agents Phase 4,Phase 3,Phase 2
29 Bronchodilator Agents Phase 4,Phase 3,Phase 2
30 Prednisolone acetate Phase 4,Phase 3
31
Salmeterol xinafoate Phase 4,Phase 2 94749-08-3 56801
32
Dexlansoprazole Phase 4,Phase 2,Phase 1 138530-94-6, 103577-45-3 9578005
33
Histamine Phosphate Phase 4,Phase 3 51-74-1 65513
34
Proton pump inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
35 Fluticasone Propionate, Salmeterol Xinafoate Drug Combination Phase 4,Phase 2
36 Adrenergic Agents Phase 4,Phase 2
37 Adrenergic Agonists Phase 4,Phase 2
38 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
39 Neuroprotective Agents Phase 4
40 Adrenergic beta-2 Receptor Agonists Phase 4,Phase 2
41 Adrenergic beta-Agonists Phase 4,Phase 2
42 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
43 Albuterol Phase 4,Phase 2
44 Tocolytic Agents Phase 4,Phase 2
45 Vasodilator Agents Phase 4
46 Endothelium-Dependent Relaxing Factors Phase 4
47 Antacids Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
48 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
49 Immunoglobulin E Phase 4
50 Prednisolone hemisuccinate Phase 4,Phase 3

Interventional clinical trials:

(show top 50) (show all 267)
id Name Status NCT ID Phase
1 Efficacy and Safety of add-on Montelukast to Inhaled Budesonide in the Treatment of Nonasthmatic Eosinophilic Bronchitis Unknown status NCT01121016 Phase 4
2 Effect of Xolair on Airway Hyperresponsiveness Unknown status NCT00208234 Phase 4
3 Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis Unknown status NCT02371941 Phase 4
4 Dietetic Versus Topical Steroids for Pediatric Eosinophilic Esophagitis Unknown status NCT01846962 Phase 4
5 Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonists Completed NCT00670930 Phase 4
6 Efficacy and Safety of Lectranal® in Treatment of Seasonal Allergic Rhinitis Symptoms Completed NCT00460538 Phase 4
7 The Efficacy of Three Months-prednisolone Therapy for Chronic Eosinophilic Pneumonia Completed NCT00632554 Phase 4
8 Regulatory Lymphocytes in Patients Treated With Specific Immunotherapy Completed NCT01475188 Phase 4
9 Small Particle Steroids in Refractory Asthma Completed NCT01171365 Phase 4
10 Steroid Treatment for Hypereosinophilic Syndrome Recruiting NCT01524536 Phase 4
11 Effect and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis Patients Recruiting NCT02605213 Phase 4
12 Exhaled NO Based Treatment of Chronic Obstructive Pulmonary Disease (COPD), ICS/LABA Versus LAMA Active, not recruiting NCT02546349 Phase 4
13 Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients Active, not recruiting NCT02654145 Phase 4
14 The Frequency of Eosinophilic Esophagitis in Patients With Heartburn That is Refractory to Proton Pump Inhibitors Terminated NCT01404832 Phase 4
15 Mepolizumab Treatment for Rhinovirus-induced Asthma Exacerbations Unknown status NCT01520051 Phase 3
16 A Study Comparing Swallowed Flovent and Placebo in Patients With Eosinophilic Disorders Completed NCT00266578 Phase 3
17 Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control Completed NCT02281318 Phase 3
18 Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma Completed NCT01508936 Phase 3
19 A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma Completed NCT01287039 Phase 3
20 A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma Completed NCT01285323 Phase 3
21 A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma Completed NCT01270464 Phase 3
22 Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease Completed NCT01576367 Phase 3
23 Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease Completed NCT01302860 Phase 3
24 Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase Completed NCT00991146 Phase 3
25 Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease Completed NCT00685373 Phase 3
26 Efficacy, Safety, and Tolerability of ACZ885 in Patients With Muckle-Wells Syndrome Completed NCT00465985 Phase 3
27 Association Corticosteroid/Azathioprine in Microscopic Polyangiitis/ Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome) Completed NCT00647166 Phase 3
28 Budesonide Orodispersible Tablet vs. Placebo in Active Eosinophilic Esophagitis Completed NCT02434029 Phase 3
29 Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis Completed NCT00635089 Phase 3
30 Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years Completed NCT00538434 Phase 2, Phase 3
31 Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant Completed NCT01305200 Phase 3
32 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
33 The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis Completed NCT00728481 Phase 2, Phase 3
34 Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00369317 Phase 3
35 Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Completed NCT00006363 Phase 3
36 Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES) Recruiting NCT02836496 Phase 3
37 Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment. Recruiting NCT02563067 Phase 3
38 Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment. Recruiting NCT02555683 Phase 3
39 A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma Recruiting NCT03052725 Phase 3
40 Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients Recruiting NCT02555371 Phase 3
41 SOFEED: Six Food vs. One Food Eosinophilic Esophagitis Diet Study Recruiting NCT02778867 Phase 2, Phase 3
42 Eosinophilic Esophagitis (EoE) Intervention Trial-Randomized 1 Food Elimination vs. 4 Food Elimination Diet Followed by Swallowed Glucocorticoids Recruiting NCT02610816 Phase 2, Phase 3
43 An Extension Study to Evaluate Maintenance of Efficacy and Long-term Treatment Effect of Oral Budesonide Suspension (OBS) in Adults and Adolescents With Eosinophilic Esophagitis (EoE) Recruiting NCT02736409 Phase 3
44 A Placebo- Controlled Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histologic Response and Determine if Reduction in Dysphagia is Achieved Recruiting NCT02605837 Phase 3
45 Maintenance of Remission With Budesonide Orodispersible Tablets vs. Placebo in Eosinophilic Esophagitis Recruiting NCT02493335 Phase 3
46 Effects of Mepolizumab Compared to Placebo on Airway Physiology in Patients With Eosinophilic Asthma: MEMORY Study Active, not recruiting NCT02594332 Phase 3
47 Treatment of Asymptomatic Toxocariasis With Albendazole in Children Active, not recruiting NCT00755560 Phase 3
48 Eosinophilic Esophagitis Treatment: Montelukast vs Fluticasone Active, not recruiting NCT01702701 Phase 3
49 Anti-Interleukin-5 (IL5) Monoclonal Antibody (MAb) in Prednisone-dependent Eosinophilic Asthma Enrolling by invitation NCT02559791 Phase 2, Phase 3
50 Trial of Ketotifen in Children and Adolescents Not yet recruiting NCT02484248 Phase 3

Search NIH Clinical Center for Hypereosinophilic Syndrome

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: eosinophilia

Genetic Tests for Hypereosinophilic Syndrome

Genetic tests related to Hypereosinophilic Syndrome:

id Genetic test Affiliating Genes
1 Eosinophilia 29
2 Hypereosinophilic Syndrome 24 PDGFRA

Anatomical Context for Hypereosinophilic Syndrome

MalaCards organs/tissues related to Hypereosinophilic Syndrome:

39
Heart, Liver, Bone, Bone Marrow, T Cells, Lung, Spleen

Publications for Hypereosinophilic Syndrome

Articles related to Hypereosinophilic Syndrome:

(show top 50) (show all 637)
id Title Authors Year
1
Hypereosinophilic syndrome. ( 28052805 )
2017
2
Eosinophilic granulomatosis with polyangiitis (formerly known as Churg-Strauss syndrome) as a differential diagnosis of hypereosinophilic syndromes. ( 28337408 )
2017
3
Idiopathic hypereosinophilic syndrome manifesting with eosinophilic cholecystitis and recurrent gastroenteritis. ( 28378039 )
2017
4
Idiopathic hypereosinophilic syndrome presenting with hepatitis and achalasia. ( 27294613 )
2016
5
Hypereosinophilic syndrome: cardiac diagnosis and management. ( 26567231 )
2016
6
Characterization of left atrial dysfunction in hypereosinophilic syndrome - Insights from the Motion analysis of the heart and great vessels by three-dimensional speckle tracking echocardiography in pathological cases (MAGYAR-Path) Study. ( 27118091 )
2016
7
Idiopathic hypereosinophilic syndrome resulting in distal aortic thromboembolism in a dog. ( 27723953 )
2016
8
Clinical features predict responsiveness to imatinib in platelet-derived growth factor receptor-alpha-negative hypereosinophilic syndrome. ( 26797802 )
2016
9
Hypereosinophilic Syndrome: A Case of Fatal LAPffler Endocarditis. ( 26904305 )
2016
10
Acute Paracoccidioidomycosis Due to Paracoccidioides brasiliensis S1 Mimicking Hypereosinophilic Syndrome with Massive Splenomegaly: Diagnostic Challenge. ( 27054891 )
2016
11
Generalized Recalcitrant Pruritus as the Presenting Manifestation of Hypereosinophilic Syndrome. ( 26826106 )
2016
12
Identification of a gain-of-function STAT3 mutation (p.Y640F) in lymphocytic variant hypereosinophilic syndrome. ( 26702067 )
2016
13
Hypereosinophilia with asthma and systemic (non-vasculitic) manifestations: Eosinophilic granulomatosis with polyangiitis or hypereosinophilic syndrome? ( 27915050 )
2016
14
Current Approach to Diagnosis and Management of Pulmonary Eosinophilic Syndromes: Eosinophilic Pneumonias, Eosinophilic Granulomatosis with Polyangiitis, and Hypereosinophilic Syndrome. ( 27231866 )
2016
15
Idiopathic hypereosinophilic syndrome presenting with severe vasculitis successfully treated with imatinib. ( 27803915 )
2016
16
IgG4-related disease and lymphocyte-variant hypereosinophilic syndrome: A comparative case series. ( 28005278 )
2016
17
Idiopathic hypereosinophilic syndrome presenting as angina pectoris: A case report. ( 27521535 )
2016
18
Frequency of abnormal T-cells in hypereosinophilic syndrome and hypereosinophilia of undetermined significance- Extended follow-up. ( 27267517 )
2016
19
Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib. ( 27887955 )
2016
20
Eosinophilic pleural effusion as a manifestation of idiopathic hypereosinophilic syndrome. ( 27185511 )
2016
21
Predictors of survival in WHO-defined hypereosinophilic syndrome and idiopathic hypereosinophilia and the role of next-generation sequencing. ( 27125206 )
2016
22
Rheumatoid arthritis heralded by the hypereosinophilic syndrome. ( 27554003 )
2016
23
Gastrointestinal and Hepatic Involvement in Hypereosinophilic Syndrome. ( 27733964 )
2016
24
Paediatric presentation of cardiac involvement in hypereosinophilic syndrome. ( 27329338 )
2016
25
Pulmonary embolism, deep vein thrombosis and recurrent bone cysts in a patient with hypereosinophilic syndrome. ( 26780165 )
2016
26
Lymphocytic variant of hypereosinophilic syndrome mimicking peripheral T-cell lymphoma in a young woman. ( 27158718 )
2016
27
Cardiac involvement in hypereosinophilic syndrome. ( 26853257 )
2016
28
Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified. ( 27174585 )
2016
29
A Possible Case of Hepatitis due to Hypereosinophilic Syndrome. ( 27250051 )
2016
30
Tolerance and Efficacy with Simultaneous Use of Two Monoclonal Antibodies for a Patient with Hypereosinophilic Syndrome and Ulcerative Colitis. ( 27911676 )
2016
31
Idiopathic Hypereosinophilic Syndrome Associated with Endomyocardial Fibrosis, Intracardiac Thrombi, Pulmonary and Skin Infiltration: A Case Report. ( 27617583 )
2016
32
Lymphocytic variant of Hypereosinophilic syndrome with deep vein thrombosis. ( 27728750 )
2016
33
Idiopathic hypereosinophilic syndrome. ( 27728301 )
2016
34
Hypereosinophilic syndrome presenting with multiple organ infiltration and deep venous thrombosis: A case report and literature review. ( 27583887 )
2016
35
Novel Chromosome 5 Inversion Associated With PDGFRB Rearrangement in Hypereosinophilic Syndrome. ( 27681117 )
2016
36
Very early stage left ventricular endocardial dysfunction of patients with hypereosinophilic syndrome. ( 27240601 )
2016
37
Hypereosinophilic Syndrome: Hacettepe Experience. ( 27548336 )
2016
38
Biventricular thrombus in hypereosinophilic syndrome presenting with shortness of breath. ( 27896330 )
2016
39
Superficial femoral artery thromosis secondary to hypereosinophilic syndrome. ( 27728032 )
2016
40
WATERSHED INFARCTION IN HYPEREOSINOPHILIC SYNDROME: A DIAGNOSTIC DILEMMA IN FIP1L1-PDGFR ALPHA-ASSOCIATED MYELOID NEOPLASM. ( 26182612 )
2015
41
A Rare Case of Aortic Valve Thrombosis in Patient with Idiopathic Hypereosinophilic Syndrome. ( 26435854 )
2015
42
Multiple cerebral infarctions in a patient with hypereosinophilic syndrome with LAPffler endocarditis: a case report. ( 25786753 )
2015
43
CD30+ clonal T-cell lymphoid proliferation of the skin in a patient with hypereosinophilic syndrome. ( 25421540 )
2015
44
Imatinib Treatment in PDGFRA-Negative Childhood Hypereosinophilic Syndrome. ( 26257279 )
2015
45
MRI-based Evidence for Myocardial Involvement in Women with Hypereosinophilic Syndrome. ( 25740233 )
2015
46
Comparison of two leukocytapheresis protocols in a case of idiopathic hypereosinophilic syndrome. ( 26463664 )
2015
47
Pyoderma gangrenosum in association with microscopic colitis, idiopathic hypereosinophilic syndrome, selective IgE deficiency and diabetes mellitus. ( 25704069 )
2015
48
Idiopathic hypereosinophilic syndrome: a new cause of vasculitis of the central nervous system. ( 25843450 )
2015
49
Treatment-refractory hypereosinophilic syndrome responding to fludarabine in a 12-year-old boy. ( 25549807 )
2015
50
Hypereosinophilic Syndrome. ( 26475367 )
2015

Variations for Hypereosinophilic Syndrome

Expression for Hypereosinophilic Syndrome

Search GEO for disease gene expression data for Hypereosinophilic Syndrome.

Pathways for Hypereosinophilic Syndrome

Pathways related to Hypereosinophilic Syndrome according to GeneCards Suite gene sharing:

(show all 44)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.81 ABL1 CCL11 CCL17 CSF2 CXCL8 FGFR1
2
Show member pathways
13.78 ABL1 CCL11 CSF2 CXCL8 EPX FGFR1
3
Show member pathways
13.58 CCL11 CCL17 CSF2 CXCL8 FGFR1 IFNA1
4
Show member pathways
13.51 ABL1 CSF2 FGFR1 IL2RA IL3 IL5
5
Show member pathways
13.49 CCL11 CCL17 CXCL8 FGFR1 IFNA1 IL13
6
Show member pathways
13.29 CCL11 CCL17 CSF2 CXCL8 FGFR1 IL13
7
Show member pathways
13.07 FGFR1 IL2RA IL3 KIT PDGFRA PDGFRB
8
Show member pathways
13.03 FGFR1 IL2RA IL3 KIT PDGFRA PDGFRB
9
Show member pathways
13 CCL11 CCL17 CSF2 CXCL8 FGFR1 IL13
10
Show member pathways
12.88 CCL11 CSF2 CXCL8 FGFR1 IFNA1 IGHE
11
Show member pathways
12.71 ABL1 FGFR1 KIT PDGFRA PDGFRB
12 12.71 ABL1 CXCL8 FGFR1 KIT PDGFRA PDGFRB
13 12.61 FGFR1 IFNA1 IL2RA IL3 KIT PDGFRA
14
Show member pathways
12.59 CSF2 IGHE IL13 IL3 IL5
15
Show member pathways
12.48 FGFR1 IL13 IL2RA IL5 PDGFRA PDGFRB
16 12.4 CSF2 IL2RA PDGFRA PDGFRB
17
Show member pathways
12.38 CCL11 CCL17 CSF2 CXCL8 IL13 IL5
18
Show member pathways
12.37 CXCL8 KIT PDGFRA PDGFRB
19
Show member pathways
12.24 CSF2 IFNA1 IL13 IL2RA IL3 IL5
20
Show member pathways
12.2 CXCL8 IFNA1 IL13 IL3 IL5
21 12.15 ABL1 FGFR1 KIT PDGFRA PDGFRB
22
Show member pathways
12.14 CSF2 IL2RA IL3 IL5
23
Show member pathways
12.14 ABL1 CCL11 CXCL8 EPX IFNA1 IL13
24 12.04 CSF2 IL2RA IL3 IL5 KIT
25 12 CCL11 CXCL8 IGHE IL13
26 11.94 CSF2 IL2RA IL3 IL5 KIT
27 11.84 CSF2 CXCL8 IL13 IL5
28 11.83 IL13 IL2RA IL5 KIT
29 11.8 FGFR1 PDGFRA PDGFRB
30
Show member pathways
11.79 CSF2 CXCL8 IL2RA IL3 IL5
31
Show member pathways
11.77 FGFR1 KIT PDGFRB
32
Show member pathways
11.77 ABL1 KIT PDGFRA PDGFRB
33 11.73 FGFR1 KIT PDGFRA PDGFRB
34 11.71 CCL11 CCL17 IGHE IL5
35 11.67 IFNA1 IL2RA IL3
36 11.65 CCL11 CSF2 CXCL8 IL13 IL5
37 11.53 CSF2 CXCL8 IL13
38 11.52 CSF2 IL3 IL5
39 11.48 FGFR1 PDGFRA PDGFRB
40 11.47 CCL11 CCL17 IL13 IL2RA IL5
41 11.33 CSF2 IL13 IL3 IL5
42 11.1 CCL11 CCL17 CSF2 CXCL8 IL13 IL3
43 10.87 IL13 IL5
44 10.84 PDGFRA PDGFRB

GO Terms for Hypereosinophilic Syndrome

Cellular components related to Hypereosinophilic Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.7 CCL11 CCL17 CSF2 CXCL8 EPX IFNA1
2 external side of plasma membrane GO:0009897 9.55 IGHE IL13 IL2RA KIT PDGFRA
3 extracellular region GO:0005576 9.44 CCL11 CCL17 CSF2 CXCL8 EPX FGFR1

Biological processes related to Hypereosinophilic Syndrome according to GeneCards Suite gene sharing:

(show all 40)
id Name GO ID Score Top Affiliating Genes
1 regulation of cell proliferation GO:0042127 9.97 ABL1 CSF2 FGFR1 KIT
2 positive regulation of cell proliferation GO:0008284 9.95 CSF2 FGFR1 IL3 IL5 KIT PDGFRA
3 positive regulation of cell migration GO:0030335 9.93 CCL11 KIT PDGFRA PDGFRB
4 cytokine-mediated signaling pathway GO:0019221 9.91 IFNA1 IL3 IL5 KIT
5 inflammatory response GO:0006954 9.91 CCL11 CCL17 CXCL8 IL13 IL2RA IL5
6 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.89 ABL1 CCL11 CCL17 PDGFRA PDGFRB
7 protein autophosphorylation GO:0046777 9.88 ABL1 FGFR1 KIT PDGFRA PDGFRB
8 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.86 ABL1 IL3 IL5
9 phosphatidylinositol-mediated signaling GO:0048015 9.86 FGFR1 KIT PDGFRA PDGFRB
10 MAPK cascade GO:0000165 9.86 CSF2 FGFR1 IL2RA IL3 IL5 KIT
11 positive regulation of GTPase activity GO:0043547 9.85 CCL11 CCL17 CSF2 FGFR1 IL2RA IL3
12 cellular response to interleukin-1 GO:0071347 9.84 CCL11 CCL17 CXCL8
13 chemokine-mediated signaling pathway GO:0070098 9.84 CCL11 CCL17 CXCL8
14 phosphatidylinositol phosphorylation GO:0046854 9.84 FGFR1 KIT PDGFRA PDGFRB
15 cell chemotaxis GO:0060326 9.83 KIT PDGFRA PDGFRB
16 neutrophil chemotaxis GO:0030593 9.83 CCL11 CCL17 CXCL8
17 regulation of phosphatidylinositol 3-kinase signaling GO:0014066 9.83 FGFR1 KIT PDGFRA PDGFRB
18 chemotaxis GO:0006935 9.83 CCL11 CCL17 CXCL8 PDGFRA PDGFRB
19 positive regulation of MAP kinase activity GO:0043406 9.81 FGFR1 KIT PDGFRB
20 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.8 CSF2 IL3 KIT
21 positive regulation of DNA replication GO:0045740 9.78 CSF2 IL3 PDGFRA
22 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.76 FGFR1 KIT PDGFRA PDGFRB
23 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.74 KIT PDGFRA PDGFRB
24 platelet-derived growth factor receptor signaling pathway GO:0048008 9.72 ABL1 PDGFRA PDGFRB
25 positive regulation of tyrosine phosphorylation of Stat5 protein GO:0042523 9.69 CSF2 IL3 KIT
26 negative regulation of interleukin-10 production GO:0032693 9.68 EPX PRG2
27 cardiac myofibril assembly GO:0055003 9.68 PDGFRA PDGFRB
28 positive regulation of podosome assembly GO:0071803 9.67 CSF2 IL5
29 response to fluid shear stress GO:0034405 9.66 CSF2 PDGFRB
30 retina vasculature development in camera-type eye GO:0061298 9.65 PDGFRA PDGFRB
31 immune response GO:0006955 9.65 CCL11 CCL17 CSF2 CXCL8 IGHE IL13
32 negative regulation of platelet-derived growth factor receptor-beta signaling pathway GO:2000587 9.64 PDGFRA PDGFRB
33 mast cell chemotaxis GO:0002551 9.62 CCL11 KIT
34 positive regulation of phospholipase C activity GO:0010863 9.62 FGFR1 KIT PDGFRA PDGFRB
35 platelet-derived growth factor receptor-beta signaling pathway GO:0035791 9.6 ABL1 PDGFRB
36 defense response to nematode GO:0002215 9.59 EPX PRG2
37 positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway GO:0038091 9.58 PDGFRA PDGFRB
38 metanephric glomerular capillary formation GO:0072277 9.58 PDGFRA PDGFRB
39 peptidyl-tyrosine phosphorylation GO:0018108 9.23 ABL1 CSF2 FGFR1 IL3 IL5 KIT
40 protein phosphorylation GO:0006468 10.1 ABL1 CCL11 FGFR1 KIT PDGFRA PDGFRB

Molecular functions related to Hypereosinophilic Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein kinase activity GO:0004672 9.85 ABL1 FGFR1 KIT PDGFRA PDGFRB
2 cytokine activity GO:0005125 9.76 CCL11 CCL17 CSF2 CXCL8 IFNA1 IL13
3 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.62 FGFR1 KIT PDGFRA PDGFRB
4 chemokine activity GO:0008009 9.58 CCL11 CCL17 CXCL8
5 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.56 FGFR1 KIT PDGFRA PDGFRB
6 protein tyrosine kinase activity GO:0004713 9.56 ABL1 CSF2 FGFR1 IL3 IL5 KIT
7 platelet-derived growth factor receptor binding GO:0005161 9.48 PDGFRA PDGFRB
8 platelet-derived growth factor binding GO:0048407 9.43 PDGFRA PDGFRB
9 vascular endothelial growth factor binding GO:0038085 9.37 PDGFRA PDGFRB
10 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.23 CSF2 FGFR1 IL2RA IL3 IL5 KIT

Sources for Hypereosinophilic Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....